



White Paper/Technical Report  
(November 2019)

## **Unlocking the Efficacy of Turmeric Root: Could the Absorption of Curcumin be the Wrong Key?**

This paper explores the conundrum between absorption, bioavailability and efficacy, as it pertains to the application of curcumin-related human clinical outcomes. We will show that, for the most part, the large increases in the absorption of curcumin using most “bioavailability-enhanced” curcumin compounds result in extremely small increases in free curcumin, subsequently resulting in only limited increases in bioactivity. Furthermore, we will discuss the evidence that suggests some of curcumin’s bioactivities may be achieved at low concentrations and that curcumin’s interaction with the human gut microbiome may be a key mechanism driving its bioactivity. Finally, we will propose that the therapeutic potential that resides within turmeric cannot be delivered by curcuminoids alone; and that the pharmaceutical approach of concentrated single entities may have been a wrong-headed approach for leveraging the therapeutic potential of turmeric in the first place.

**The Point Institute** is an independent research organization focused on examining and disseminating information about the use of natural therapeutic options for treating and preventing chronic disease. We provide these technical reports as research summaries only—they are not intended to be used in place of sound medical advice by a licensed health care practitioner.

**The Point Institute**  
**Director: Thomas Guilliams Ph.D.**  
**Website: [www.pointinstitute.org](http://www.pointinstitute.org)**  
**Email: [info@pointinstitute.org](mailto:info@pointinstitute.org)**

## Introduction

Clinical research and therapeutic use of botanically derived ingredients continue to grow worldwide. This includes ingredients that are minimally processed (e.g., ginger root powder), as well as those that are highly concentrated compounds (e.g., quercetin). While many botanical preparations have been used for millennia in various medicinal traditions (numerous of which are recorded in ancient pharmacopeias), some have also been evaluated using the latest drug discovery techniques. Turmeric (*Curcuma longa* L. and related species), and several of its phytochemicals (e.g., curcuminoids), is one of the most notable (and popular) botanicals to reach both ends of the spectrum.

The use of turmeric as a culinary and medicinal herb has been recorded for nearly 4000 years. In Ayurveda and Traditional Chinese Medicine, turmeric has been well documented as an anti-inflammatory agent to treat various ailments such as arthritis, jaundice, hepatic disorders, digestive disorders, gynecological problems, skin diseases, cough, cold and dental problems.<sup>1,2</sup> Turmeric powder has also been used ubiquitously as a flavoring, coloring and beautifying agent in Southeast Asia. The root and rhizome of this perennial herb are usually boiled, cleaned, dried and ground, yielding a bright yellow colored powder.<sup>3</sup>

Despite these historical uses, and identification of many bioactive components in turmeric, the research focus over the past few decades has been almost exclusively centered on one group of phytochemical compounds from turmeric, its curcuminoids. Purified and concentrated extracts of one or more curcuminoids (often 95% or greater) are commonly used in dietary supplements, functional foods, and clinical research trials across the globe (over 8,000 citations in PubMed include “curcumin” in their title!). However, despite its popularity and hopeful research, the clinical results using curcumin in humans is often greatly muted compared to the promising results from *in vitro* research and mechanistic studies. The reason for this disparity is almost universally attributed to curcumin’s poor absorption/bioavailability, for which the creation of a variety of bioavailability-enhanced delivery forms has been postulated as the logical solution.

Today, at least a dozen different ingredients are commercially available that are specifically designed to increase the oral absorption of curcumin, using a variety of different technologies (e.g., liposomes, nanotechnologies, micelles, etc.). Indeed, most of these complexes have been shown to result in much higher serum levels of curcumin compounds, when compared with unmodified 95% curcumin preparations. However, despite the claims being made about these modified ingredients, their increased absorption has not yet been demonstrated to significantly increase clinical efficacy in human clinical trials.<sup>4</sup>


In this paper we will explore the conundrum between absorption, bioavailability and efficacy, as it pertains to the application of curcumin-related human clinical outcomes. We will show that, for the most part, the large increases in the absorption of curcumin using most “bioavailability-enhanced” curcumin compounds result in extremely small increases in free curcumin, subsequently resulting in only limited increases in bioactivity. This will lead us into a discussion of the ongoing debate about which curcumin metabolites are considered to be the most bioactive when consumed orally. Furthermore, we will discuss the evidence that suggests some of curcumin’s bioactivities may be achieved at low concentrations and that curcumin’s interaction with the human gut microbiome (a bioactivity which may not even require human

bioavailability) may be a key mechanism driving its bioactivity. Finally, we will propose that the therapeutic potential that resides within turmeric cannot be delivered by curcuminoids alone; and that the pharmaceutical approach of concentrated single entities may have been a wrong-headed approach for leveraging the therapeutic potential of turmeric in the first place.

### **The Basic Phytochemistry of Turmeric**

Turmeric, a perennial native to South Asia, is the common name of *Curcuma longa*, of which the rhizome is the most extensively used part. Other synonyms of *Curcuma longa* include *Curcuma aromatica*, *Curcuma wenyujin* and *Curcuma domestica*.<sup>5</sup> The most abundant compounds from turmeric include carbohydrates (60-70%), water (6-13%), proteins (6-8%), fatty acids (5-10%), essential oils (3-7%), minerals (3-7%), fiber (2-7%) and curcuminoids (2-6%).<sup>6</sup> However, more than 235 different compounds have been reported in turmeric extracts, mainly phenolic compounds and terpenoids.<sup>3</sup> Turmeric extracts are generally prepared using solvents like ethanol, methanol, water or ethyl acetate. Essential oil preparations, obtained by steam distillation of the rhizome, have been reported to contain 84 different chemical constituents; including sesquiterpenes (53%), zingiberene (25%),  $\alpha$ -phellandrene (1%), sabinene (0.6%), cineol (1%), and borneol (0.5%).<sup>7,8</sup> The  $\alpha$ - and  $\beta$ - turmerones and ar-turmerones (sesquiterpenes) present in the essential oil of turmeric are primarily responsible for its aroma.<sup>6</sup> In the midst of all these phytochemicals, the pharmacological activity of turmeric has been attributed mostly to polyphenolic curcuminoids; therefore turmeric research has mostly focused on the isolation and use of curcuminoids/curcumin.

Curcuminoids are a mixture of turmeric-derived phenolic compounds that include curcumin (diferuloylmethane), demethoxycurcumin and bisdemethoxycurcumin, which give turmeric their characteristic yellow/orange color. Curcuminoids are typically extracted from the dried rhizome using solvent extraction and column chromatography using consecutive non-polar and polar solvents.<sup>8,9</sup> A typical composition of Indian varieties of curcuminoids consist of 52-63% curcumin, 19-27% demethoxycurcumin and 18-28% bisdemethoxycurcumin.<sup>10</sup> Highly concentrated forms of these turmeric extracts are obtained by further purification and crystallization of the initial extract (initially containing about 40% curcuminoids).<sup>11</sup> Most of the commercially available curcuminoid ingredients used for therapeutic and research purposes are standardized to contain 95% curcuminoids; of which 70-80% is curcumin, 15-25% is demethoxycurcumin and 2.5-6.5% is bisdemethoxycurcumin.<sup>10,12</sup> The term “curcumin,” in both research publications and on product labels, is often confusing and incorrect; since it can refer to a purified curcumin-only ingredient (most often used for research purposes), though it is most often describing (incorrectly) a purified extract containing all 3 major curcuminoids.



**Figure 1: Chemical structure of curcuminoids<sup>13</sup>**

## **Bioactivities of Curcuminoids**

As mentioned, most of the clinical research using turmeric-derived compounds is focused exclusively on the activities of curcuminoids (including dozens of synthetic analogs of curcumin). Since the term “curcumin” is not always distinguished from curcuminoids in the materials and methods section of a publication, it can sometimes be difficult to know whether the ingredient used was a pure form of curcumin (i.e., 100% diferuloylmethane) or is a purified extract containing the three typical curcuminoids in commercially-prepared turmeric root extracts. While this distinction may be subtle, there are those that suggest these differences can greatly influence its efficacy.<sup>14</sup> Nonetheless, curcumin/curcuminoids and their synthetic analogs have been tested in nearly every possible *in vitro* assay and drug discovery protocol, attempting to uncover their potential therapeutic mechanisms.

After isolation of curcumin by Vogel and Pelletier, the first scientific biological activity of curcumin was recorded in 1949 as an anti-bacterial agent.<sup>15</sup> Further interest in curcumin’s potential as a modern medicine was sparked in the early 1970s when cholesterol-lowering, anti-diabetic, anti-inflammatory, and antioxidant properties were recognized. Extensive biomedical research on curcumin has increased considerably since then, revealing a wide range of potential therapeutic benefits. The pleiotropic effects attributed to curcuminoids have been demonstrated primarily by various cell-based *in vitro* assays and preclinical animal studies.<sup>10</sup> These studies have identified numerous curcumin-related targets and mechanisms at the molecular level including a) transcription factors such as NF- $\kappa$ B, STAT3, Egr-1, PPAR- $\gamma$  and  $\beta$ -catenin<sup>16</sup> b) modulation of enzyme activity<sup>17,18</sup> such as COX-2, 5-LOX, iNOS, MMPs, caspases, protein kinases<sup>19</sup> (MAPK, JNK, PKA, PKC, src tyrosine kinase, phosphorylase kinase) c) inflammatory cytokines such as IL -1, -2, -6, -8, -12, TNF- $\alpha$  d) growth factors and their receptors and e) adhesion molecules like ICAM-1, VCAM-1, and ELAM-1. More recent research has suggested curcuminoids modulate the expression of non-coding RNA and may affect gene expression through epigenetic pathways.<sup>20-23</sup>

Based on the promising results of these types of studies, it is not surprising that curcumin has become a leading candidate for drug development. However, translating *in vitro* research results into similar clinical outcomes has been met with limited success. Though some have speculated that the *in vitro* results are themselves misleading, most researchers believe that these failures are due to curcumin being poorly absorbed, highly reactive and unstable after consumption.<sup>24</sup> Therefore, despite the historical therapeutic benefits attributed to various turmeric preparations, including many publications of clinical benefit using concentrated curcumin products (discussed in a later section), there has been an emphasis on finding ways to increase the absorption and stability of curcumin preparations, or on synthesizing curcumin-like synthetic compounds that have better clinical outcomes.

## **Absorption and Metabolism of Curcumin**

Pharmacokinetic-type studies of curcumin in humans generally show a very low recovery of curcumin in the serum after oral intake. One study indicated that the amount of free curcumin in human plasma after intake of 3.6-12 g curcumin for a week or longer was below 25 nM<sup>25</sup> (for comparison, concentrations typically used in *in vitro* studies mostly range from 1-80  $\mu$ M). The reasons for this low recovery are many, and include processes that affect the intestinal absorption

of curcuminoids and several different metabolic steps that occur in the gut lumen, within the enterocytes, in the liver and within target tissues.<sup>26</sup> Curcuminoids undergo extensive metabolism during and after ingestion.<sup>26</sup> Bioreduction of curcuminoids through phase I metabolism forms major products like tetrahydrocurcumin and hexahydrocurcumin. Further, curcumin and its reduced forms are extensively conjugated through phase II glucuronidation and sulfation; leading to formation of conjugated metabolites like curcumin glucuronide, curcumin sulfate, curcumin sulfate-glucuronide, dihydrocurcumin-glucuronide and tetrahydrocurcumin-glucuronide, etc. While some have speculated biological activity for some of these metabolites<sup>27</sup>, the *in vitro* assessment of the biological activity of the phase II metabolites of curcumin has demonstrated that predominant serum metabolites, like curcumin glucuronides, do not possess significant bioactivity, compared to free curcumin.<sup>28-30</sup> Additionally, while small curcumin metabolites that have been isolated from *in vitro* studies (such as vanillin and ferulic acid and their derivatives) have been shown to have potential therapeutic effects, little is known about their formation, pharmacokinetics and bioactivity in animals or humans after oral ingestion of curcuminoids.<sup>31,32</sup>

Therefore, while curcumin metabolites and conjugates are an important part of the pharmacokinetic profile when assessing the bioavailability of curcumin (though they are often not reported in these studies), limited information is available on how these compounds affect the potential therapeutic outcomes in human subjects consuming turmeric or curcumin products. Furthermore, recent studies suggest that curcuminoids can be modified by certain bacteria residing in the human gut microbiome. The relationship between these metabolites and curcumin's potential therapeutic benefits (mediated through microbiota, directly on cells of the intestinal tract or by systemic absorption) is an area of current investigation (covered briefly in a later section).

### **Modifying Curcumin to Enhance Absorption**

Although there is ample evidence that oral intake of turmeric extracts and concentrated curcumin ingredients (typically 95% curcuminoids) have measurable clinical effects for a variety of outcomes,<sup>1,33-38</sup> it is generally assumed that the poor bioavailability of curcumin prevents high levels of bioactive compounds from reaching relevant tissues, thereby limiting these effects. This conclusion is especially common when comparing the clinical benefits seen with oral intake of curcuminoids with those from cell culture studies.<sup>†</sup> Equally common is the assumption that technologies designed to improve the bioavailability of curcumin will increase its bioactivity, allowing researchers to realize many of the predicted *in vitro* benefits in animal or human subjects after oral intake of these modified curcumin preparations.<sup>12</sup>

A variety of technologies have been designed to resolve the problem of curcumin's low bioavailability and metabolic inactivation after oral ingestion.<sup>39-43</sup> These technologies include the mixture of agents designed to prevent the efflux and metabolism of curcumin in the enterocyte (piperine) and a range of drug delivery systems such as nanoparticles, liposomes, micelles or phospholipid complexes; a great number of which are commercially available to consumers and researchers. Indeed, both animal and human clinical trials confirm an increase in serum levels of

---

<sup>†</sup> While it is beyond the scope of our discussion, there are significant potential differences in the curcumin metabolites that form *in vitro*, with those that occur *in vivo* (which are greatly affected by the cell culture medium, light, pH and other factors). It is quite possible that some of the promising *in vitro* results are a consequence of high levels of curcumin metabolites that may not be present after ingestion in mammals, further complicating the translation of these potential bioactivities.

total curcuminoids with most commercially available “enhanced” forms of curcumin, when compared to the unmodified curcumin (i.e., 95% curcuminoid).<sup>10</sup> Published reports have suggested up to 20 times increase in serum levels with curcumin+piperine, 6.93 times increase with Biocurcmax, 8.88 times increase with Meriva<sup>44</sup>, 9 times increase with micronized curcumin<sup>42</sup>, 27 times increase with Theracurmin<sup>41</sup>, 45.9 times increase with CurcuWIn<sup>43</sup>, 185 fold increase with Novasol<sup>42</sup> etc. We should note that these increases are almost always measured as the difference of the serum levels (area under the curve, AUC) over a specified time after ingestion, and usually includes all curcumin compounds (i.e., including glucuronide and sulfate conjugates). Free curcumin levels, when reported, are significantly lower in their respective differences compared to the total.<sup>41-45</sup>

As it turns out, this difference is likely to be very important in explaining why the dramatic increases in serum levels of curcumin that result from using these enhanced forms of curcumin have yet to result in efficacy differences that mirror these same increases (if they increase their efficacy at all). In other words, the vast majority of the increase in curcumin levels in the blood after ingestion of these enhanced forms is conjugated (as a glucuronide or sulfide) and, most likely, has little therapeutic benefit. However, what makes this difficult to discover when reading these publications is the fact that these data are typically reported as total curcumin, total curcuminoids or just curcumin. One needs to dig into the materials and methods section of these publications to discover that the serum samples are treated with glucuronidase and sulfatase enzymes, effectively converting all the compounds to “free” curcumin.<sup>‡46</sup> Therefore, while large increases in total curcumin are realized by using a variety of enhanced-forms of curcuminoids, the increase in bioactive curcumin reaching tissues is likely to be very limited since the majority (~95%+) of the absorbed curcumin is in the conjugated forms. Thus, we conclude that these enhanced forms of curcumin increase absorption, but it is misleading to say that these compounds have improved bioavailability (i.e., tissue availability of the bioactive form).

### **Comparing Bioactivity of Enhanced vs Non-Enhanced Curcumins**

As mentioned previously, the past three decades have witnessed a large number of clinical studies, including a multitude of randomized controlled clinical trials, investigating the therapeutic benefits of various turmeric and curcumin preparations, with varying degrees of clinical benefit. Likewise, since the invention of various enhanced forms of curcumin, clinical studies have investigated their potential benefits in many clinical trials. However, while nearly all the enhanced forms of curcumin have been compared (head-to-head) against 95% curcumin in measures of absorption (often incorrectly called bioavailability- see above), there are no published studies which compare these enhanced forms with 95% curcumin using a clinical outcome (i.e., therapeutic effect).<sup>47-52</sup> Instead, like the earlier studies using unenhanced forms of turmeric or curcumin, they have been compared to placebo, or in some cases, to other relevant active ingredients such as a known anti-inflammatory agent. One would imagine that since these enhanced forms were created with a goal to resolve a recognized efficacy gap (the assumption that efficacy was hindered by poor bioavailability), that comparing their therapeutic outcomes with unenhanced curcumin preparations would have been a high priority once absorption enhancement had been established. The lack of interest in this question (or the lack of published

---

<sup>‡</sup> The detection of free curcumin in the presence of its metabolites and conjugates is not straightforward and has only recently been refined.<sup>46</sup>

data to answer it) is problematic, especially since the primary marketing strategy in the sale of these new ingredients implies greater efficacy at lower doses.

Even without direct head-to-head studies, those who have objectively assessed the clinical effects of both enhanced and unenhanced curcumins conclude that they have similar efficacy in human subjects. In fact, one review article on the subject attempts to tackle this conundrum: “*The collected outcomes raise an open question: why significantly improved bioavailability of curcumin does not produce improved pharmacological efficacy in many studies? Here, we attempt to explain the reason that enhanced bioavailability of curcumin is not associated with improved pharmacological efficacy.*”<sup>4</sup> While they use the term “bioavailability” to mean absorption, they also say that efficacy is not different in *many* studies; implying that efficacy is improved in some studies using enhanced forms of curcumin. Ironically, no human study is cited in their review that shows improved efficacy of the enhanced forms of curcumin over the unenhanced forms.

Regardless, two lines of evidence suggest that the difference in efficacy between the enhanced forms and the unenhanced forms is likely to be limited. The first we have already mentioned, that the majority of the increase in curcumin absorption is almost all found in the conjugated glucuronide and sulfate forms and only small increases in free curcumin (or other potentially active metabolites) are realized. The second is that most of the formulations used to increase the absorption of curcumin are likely to alter the interface between curcuminoids and gut microbes and/or other active sites within the gut lumen. Since emerging research suggests that some of curcumin’s local and systemic effects require interaction with gut microbiota, it is possible that these effects are diminished in many of the commercially available enhanced curcumin formulations.

### **The Emerging Role of Gut Microbiota**

The human gut microbiome is now considered to influence nearly every aspect of human metabolism and health; and is also recognized as an important mediator of phytonutrient therapeutic activities.<sup>53,54</sup> In fact, since many bioactive phytonutrients have naturally low bioavailability/absorption, resulting in relatively high intestinal concentrations after oral ingestion, researchers have begun to consider the gut and its microbiota as the primary target of phytonutrients like curcumin.<sup>55-57</sup> Indeed, during the past several years scientific advances have suggested a strong bidirectional interconnection between the human gut microbiome and curcumin; whereby curcumin metabolism is influenced by certain gut microbiota and curcumin metabolites modulate the function and therapeutic activities of certain gut microbes.<sup>58</sup> In addition, neurohormonal signaling from the gut (e.g., gut/brain, etc.) appear to be modulated by curcumin administration. Therefore, despite its low systemic bioavailability, these emerging studies may help to explain some of curcumin’s systemic pharmacological activities and mechanisms of action despite its low systemic bioavailability.

- Dose- dependent administration of curcumin has been shown to alter the makeup of gut microbiota in animal models affecting the management of obesity<sup>59</sup>, colitis<sup>60</sup>, non-alcoholic fatty liver disease; including microbiota changes induced by a high-fat diet.<sup>61</sup>
- Production of the bacterial endotoxin, lipopolysaccharides (LPS), which can be induced with “Western” diet challenge in animals, was significantly lowered with curcumin supplementation.<sup>62</sup> This same model showed curcumin’s ability to improve measures of gut barrier function that was deteriorated with the same diet challenge.

- Studies show that specific bacterial species isolated from human gut or stool samples are capable of metabolizing curcuminoids to bioactive metabolites; some of which cannot be produced without microbe biotransformation.<sup>63-69</sup>
- Administration of curcumin significantly ameliorated alterations in neurotransmitters such as 5-HT (serotonin), BDNF (Brain-derived neurotrophic factor) and pCREB (phosphorylation of cAMP response element-binding protein ) in the hippocampus and colon of a rat model of IBS-induced anxiety.<sup>70,71</sup>
- Curcumin exhibited anti-arthritic effects by improving the cholinergic anti-inflammatory system, increasing the synthesis of the neurotransmitter, acetylcholine, through the stimulation of the vagus nerve.<sup>72,73</sup>

### **Beyond Curcumin: The Other Bioactives in Turmeric**

For historical reasons, the therapeutic potential of turmeric has been disproportionately focused on curcuminoids, which make up only around 5% of the total weight of turmeric root. However, clinical trials have shown that preparations of whole turmeric or turmeric preparations not designed to concentrate curcuminoids have shown some clinical benefit. These include trials demonstrating biological activities of turmeric when used alone or as an adjuvant therapy in the management and treatment of inflammatory diseases<sup>74</sup>, rheumatoid arthritis<sup>75</sup>, osteoarthritis<sup>38,76</sup>, autoimmune disorders like lupus nephritis<sup>77</sup>, cancer<sup>78-80</sup>, diabetes<sup>81,82</sup>, irritable bowel syndrome<sup>83,84</sup>, mutagens<sup>85</sup> and fibrosis.<sup>86</sup> In an *in vitro* antiproliferation study, whole turmeric preparation had stronger growth-inhibitory effects compared to concentrated curcumin alone (both delivered the same level of curcumin) in various cancer cell lines.<sup>87</sup> Another study reported that a turmeric oil-rich extract was more effective than curcumin in inhibiting prostaglandin E2; whereas it had no effect in inhibiting cyclooxygenase-2 (COX-2), like curcumin did.<sup>88</sup> These studies highlight the importance of the multi-component therapeutic potency of turmeric; showing that its therapeutic efficacy may be attributed to non-curcuminoid compounds, as well as the synergy between these compounds and curcuminoids.

In fact, while most researchers have been focusing on the promise of increased curcumin bioavailability, many others have been finding therapeutic activities attributed to many of the non-curcuminoid compounds in turmeric, especially related to anti-inflammatory and anti-cancer outcomes.<sup>5,89</sup> These include compounds such as turmerin<sup>90-93</sup>, turmerones<sup>94-96</sup>, elemene<sup>97,98</sup>, furanodiene<sup>99</sup>, curdione<sup>100-102</sup>, bisacurone<sup>103</sup>, cyclocurcumin<sup>104-106</sup>, calebin A<sup>107-109</sup>, and germacrone.<sup>110-112</sup> Preliminary clinical studies even suggest that curcumin-free extracts can reduce markers of pain and inflammation, actions which are usually assumed to require curcumin.<sup>113</sup>

### **A way forward**

As other botanicals have, turmeric root has bridged the gap between an ancient medicinal herb and a modern phytopharmaceutical. However, in that transition a disproportionate focus has been placed upon the therapeutic potential of one set of constituents- its curcuminoids; in the hopes that these compounds would unlock turmeric's medicinal treasures. Though we agree that curcuminoids are indeed an important participant in the therapeutic potential of turmeric root, and we have learned much by using purified and concentrated curcuminoid preparations; it is important to acknowledge the limitations that curcumin-only therapy has produced. While these limitations were assumed to be based on curcumin's poor bioavailability, the fact that enhanced



forms of curcumin designed to greatly increase its absorption and serum levels have not yet been shown to improve therapeutic activities in human subjects suggests there is more to the story. Ironically, human biology appears to limit the accumulation of free curcumin and quickly forms inactive conjugates, which appears to nullify most of the gains achieved in increasing curcumin's absorption using almost every technology implemented so far. Therefore, we believe further attempts to improve absorption are likely to meet the same efficacy-related barriers. Though synthetic curcuminoids or concomitant use of compounds that inhibit the formation of curcumin conjugates may be discovered, the safety parameters of these sorts of solutions must be verified before testing their efficacy in human subjects. These types of phytopharmaceutical solutions may have specific applications in medicine; however, they fall far outside the original use of the turmeric root.

We believe the key to unlock the clinical benefits of turmeric are best accomplished by delivering curcuminoids within the context of other turmeric-derived phytochemicals, rather than by new technologies designed to increase the absorption/bioavailability of curcumin concentrates. Emerging mechanistic data has revealed the activities of many non-curcuminoid, turmeric-derived compounds and preliminary studies using curcumin-free turmeric preparations have shown clinically relevant outcomes. In addition, we believe that since many of the proposed mechanisms for curcumin (and other turmeric-derived compounds) can be facilitated by low doses in the human serum (genomic, epigenetic and hormetic) or by interaction with the human gut microbiota (requiring little or no systemic absorption), that technologies designed to increase curcumin absorption may be unnecessary or even counterproductive for most therapeutic outcomes. Thankfully, researchers are beginning to look beyond curcumin in their attempts to leverage turmeric's therapeutic potential and it is our hope that additional research will establish the best way to deliver curcuminoids, within the context of other turmeric-derived phytonutrients. This will allow us to establish the range of therapeutic potential for the whole turmeric root complex, allowing for synergy with other botanicals and nutrients to allow for safe, effective and predictable therapeutic outcomes.

## References

1. Gupta SC, Sung B, Kim JH, Prasad S, Li S, Aggarwal BB. Multitargeting by turmeric, the golden spice: From kitchen to clinic. *Molecular Nutrition & Food Research*. 2013;57(9):1510-1528.
2. Prasad S, Aggarwal BB. Turmeric, the Golden Spice: From Traditional Medicine to Modern Medicine. In: nd, Benzie IFF, Wachtel-Galor S, eds. *Herbal Medicine: Biomolecular and Clinical Aspects*. Boca Raton (FL)2011.
3. Li S. *Chemical Composition and Product Quality Control of Turmeric (Curcuma longa L.)*. Vol 52011.
4. Ji HF, Shen L. Can improving bioavailability improve the bioactivity of curcumin? *Trends Pharmacol Sci*. 2014;35(6):265-266.
5. Aggarwal BB, Yuan W, Li S, Gupta SC. Curcumin-free turmeric exhibits anti-inflammatory and anticancer activities: Identification of novel components of turmeric. *Mol Nutr Food Res*. 2013;57(9):1529-1542.
6. edited by P.N. Ravindran KNB, Sivaraman K. *Turmeric : the genus Curcuma*. Boca Raton, FL : CRC Press, [2007] ©2007; 2007.
7. Amalraj A, Pius A, Gopi S, Gopi S. Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - A review. *Journal of traditional and complementary medicine*. 2016;7(2):205-233.
8. Agarwal S, Mishra R, Gupta AK, Gupta A. Chapter 5 - Turmeric: isolation and synthesis of important biological molecules. In: Tewari A, Tiwari S, eds. *Synthesis of Medicinal Agents from Plants*. Elsevier; 2018:105-125.
9. Takenaka M, Ohkubo T, Okadome H, Sotome I, Itoh T, Isobe S. Effective Extraction of Curcuminoids by Grinding Turmeric (*Curcuma longa*) with Medium-chain Triacylglycerols. *Food Science and Technology Research*. 2013;19(4):655-659.

10. Siviero A, Gallo E, Maggini V, et al. Curcumin, a golden spice with a low bioavailability. *Journal of Herbal Medicine*. 2015;5(2):57-70.
11. Kendrick A. 2 - Natural food and beverage colourings. In: Baines D, Seal R, eds. *Natural Food Additives, Ingredients and Flavourings*. Woodhead Publishing; 2012:25-40.
12. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. *Mol Pharm*. 2007;4(6):807-818.
13. Xu XY, Meng X, Li S, Gan RY, Li Y, Li HB. Bioactivity, Health Benefits, and Related Molecular Mechanisms of Curcumin: Current Progress, Challenges, and Perspectives. *Nutrients*. 2018;10(10).
14. Cavaleri F. Presenting a New Standard Drug Model for Turmeric and Its Prized Extract, Curcumin. *Int J Inflam*. 2018;2018:5023429.
15. Schraufstatter E, Bernt H. Antibacterial action of curcumin and related compounds. *Nature*. 1949;164(4167):456.
16. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. *Adv Exp Med Biol*. 2007;595:127-148.
17. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. *Cancer Lett*. 2001;172(2):111-118.
18. Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-kappaB activation through inhibition of IkkappaBalpha kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. *Carcinogenesis*. 2003;24(7):1269-1279.
19. Hamzehzadeh L, Atkin SL, Majeed M, Butler AE, Sahebkar A. The versatile role of curcumin in cancer prevention and treatment: A focus on PI3K/AKT pathway. *Journal of Cellular Physiology*. 2018;233(10):6530-6537.
20. Teiten MH, Dicato M, Diederich M. Curcumin as a regulator of epigenetic events. *Mol Nutr Food Res*. 2013;57(9):1619-1629.
21. Gao Y, Tollefsbol TO. Impact of Epigenetic Dietary Components on Cancer through Histone Modifications. *Curr Med Chem*. 2015;22(17):2051-2064.
22. Mirzaei H, Masoudifar A, Sahebkar A, et al. MicroRNA: A novel target of curcumin in cancer therapy. *J Cell Physiol*. 2018;233(4):3004-3015.
23. Liu T, Chi H, Chen J, et al. Curcumin suppresses proliferation and in vitro invasion of human prostate cancer stem cells by ceRNA effect of miR-145 and lncRNA-ROR. *Gene*. 2017;631:29-38.
24. Nelson KM, Dahlin JL, Bisson J, Graham J, Pauli GF, Walters MA. The Essential Medicinal Chemistry of Curcumin. *J Med Chem*. 2017;60(5):1620-1637.
25. Villegas I, Sánchez-Fidalgo S, Alarcón de la Lastra C. New mechanisms and therapeutic potential of curcumin for colorectal cancer. *Molecular Nutrition & Food Research*. 2008;52(9):1040-1061.
26. Heger M, van Golen RF, Broekgaarden M, Michel MC. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. *Pharmacol Rev*. 2014;66(1):222-307.
27. Jacob J, Amalraj A, Raj KKJ, Divya C, Kunnumakkara AB, Gopi S. A novel bioavailable hydrogenated curcuminoids formulation (CuroWhite™) improves symptoms and diagnostic indicators in rheumatoid arthritis patients - A randomized, double blind and placebo controlled study. *Journal of Traditional and Complementary Medicine*. 2018.
28. Pal A, Sung B, Bhanu Prasad BA, et al. Curcumin glucuronides: assessing the proliferative activity against human cell lines. *Bioorganic & medicinal chemistry*. 2014;22(1):435-439.
29. Shoji M, Nakagawa K, Watanabe A, et al. Comparison of the effects of curcumin and curcumin glucuronide in human hepatocellular carcinoma HepG2 cells. *Food Chem*. 2014;151:126-132.
30. Kunihiro AG, Brickey JA, Frye JB, Luis PB, Schneider C, Funk JL. Curcumin, but not curcumin-glucuronide, inhibits Smad signaling in TGFbeta-dependent bone metastatic breast cancer cells and is enriched in bone compared to other tissues. *J Nutr Biochem*. 2019;63:150-156.
31. Tsuda T. Curcumin as a functional food-derived factor: degradation products, metabolites, bioactivity, and future perspectives. *Food Funct*. 2018;9(2):705-714.
32. Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products? *Trends Mol Med*. 2012;18(3):138-144.

33. Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. *Clin Cancer Res*. 2008;14(14):4491-4499.
34. Yang YS, Su YF, Yang HW, Lee YH, Chou JI, Ueng KC. Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial. *Phytother Res*. 2014;28(12):1770-1777.
35. Chuengsamarn S, Rattanamongkolgul S, Luechapudiporn R, Phisalaphong C, Jirawatnotai S. Curcumin extract for prevention of type 2 diabetes. *Diabetes Care*. 2012;35(11):2121-2127.
36. Yang H, Xu W, Zhou Z, et al. Curcumin attenuates urinary excretion of albumin in type II diabetic patients with enhancing nuclear factor erythroid-derived 2-like 2 (Nrf2) system and repressing inflammatory signaling efficacies. *Exp Clin Endocrinol Diabetes*. 2015;123(6):360-367.
37. Yu JJ, Pei LB, Zhang Y, Wen ZY, Yang JL. Chronic Supplementation of Curcumin Enhances the Efficacy of Antidepressants in Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Pilot Study. *J Clin Psychopharmacol*. 2015;35(4):406-410.
38. Kuptniratsaikul V, Dajpratham P, Taechaarpornkul W, et al. Efficacy and safety of Curcuma domestica extracts compared with ibuprofen in patients with knee osteoarthritis: a multicenter study. *Clin Interv Aging*. 2014;9:451-458.
39. Gopi S, Jacob J, Varma K, et al. Comparative Oral Absorption of Curcumin in a Natural Turmeric Matrix with Two Other Curcumin Formulations: An Open-label Parallel-arm Study. *Phytother Res*. 2017;31(12):1883-1891.
40. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. *Cancer Chemother Pharmacol*. 2007;60(2):171-177.
41. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. *Biol Pharm Bull*. 2011;34(5):660-665.
42. Schiborr C, Kocher A, Behnam D, Jandasek J, Toelstede S, Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes. *Molecular Nutrition & Food Research*. 2014;58(3):516-527.
43. Jäger R, Lowery RP, Calvanese AV, Joy JM, Purpura M, Wilson JM. Comparative absorption of curcumin formulations. *Nutrition journal*. 2014;13:11-11.
44. Cuomo J, Appendino G, Dern AS, et al. Comparative Absorption of a Standardized Curcuminoid Mixture and Its Lecithin Formulation. *Journal of Natural Products*. 2011;74(4):664-669.
45. Kanai M, Otsuka Y, Otsuka K, et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients. *Cancer Chemother Pharmacol*. 2013;71(6):1521-1530.
46. Kunati SR, Yang S, William BM, Xu Y. An LC-MS/MS method for simultaneous determination of curcumin, curcumin glucuronide and curcumin sulfate in a phase II clinical trial. *J Pharm Biomed Anal*. 2018;156:189-198.
47. Santos-Parker JR, Strahler TR, Bassett CJ, Bispham NZ, Chonchol MB, Seals DR. Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress. *Aging (Albany NY)*. 2017;9(1):187-208.
48. Cox KH, Pipingas A, Scholey AB. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population. *J Psychopharmacol*. 2015;29(5):642-651.
49. Di Pierro F, Zacconi P, Bertuccioli A, et al. A naturally-inspired, curcumin-based lecithin formulation (Meriva(R)) formulated as the finished product Algocur(R)) alleviates the osteo-muscular pain conditions in rugby players. *Eur Rev Med Pharmacol Sci*. 2017;21(21):4935-4940.
50. Small GW, Siddarth P, Li Z, et al. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial. *Am J Geriatr Psychiatry*. 2018;26(3):266-277.
51. Belcaro G, Hosoi M, Pellegrini L, et al. A controlled study of a lecithinized delivery system of curcumin (Meriva(R)) to alleviate the adverse effects of cancer treatment. *Phytother Res*. 2014;28(3):444-450.
52. Sterzi S, Giordani L, Morrone M, et al. The efficacy and safety of a combination of glucosamine hydrochloride, chondroitin sulfate and bio-curcumin with exercise in the treatment of knee osteoarthritis: a randomized, double-blind, placebo-controlled study. *Eur J Phys Rehabil Med*. 2016;52(3):321-330.

53. Espin JC, Gonzalez-Sarrias A, Tomas-Barberan FA. The gut microbiota: A key factor in the therapeutic effects of (poly)phenols. *Biochem Pharmacol*. 2017;139:82-93.
54. Kawabata K, Yoshioka Y, Terao J. Role of Intestinal Microbiota in the Bioavailability and Physiological Functions of Dietary Polyphenols. *Molecules*. 2019;24(2).
55. Lopresti AL. The Problem of Curcumin and Its Bioavailability: Could Its Gastrointestinal Influence Contribute to Its Overall Health-Enhancing Effects? *Adv Nutr*. 2018;9(1):41-50.
56. Zam W. Gut Microbiota as a Prospective Therapeutic Target for Curcumin: A Review of Mutual Influence. *J Nutr Metab*. 2018;2018:1367984.
57. Chen F, Wen Q, Jiang J, et al. Could the gut microbiota reconcile the oral bioavailability conundrum of traditional herbs? *J Ethnopharmacol*. 2016;179:253-264.
58. Shen L, Ji HF. Bidirectional interactions between dietary curcumin and gut microbiota. *Crit Rev Food Sci Nutr*. 2018:1-28.
59. Zhang Z, Chen Y, Xiang L, Wang Z, Xiao GG, Hu J. Effect of Curcumin on the Diversity of Gut Microbiota in Ovariectomized Rats. *Nutrients*. 2017;9(10).
60. McFadden RM, Larmonier CB, Shehab KW, et al. The Role of Curcumin in Modulating Colonic Microbiota During Colitis and Colon Cancer Prevention. *Inflamm Bowel Dis*. 2015;21(11):2483-2494.
61. Feng W, Wang H, Zhang P, et al. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. *Biochim Biophys Acta Gen Subj*. 2017;1861(7):1801-1812.
62. Ghosh SS, Bie J, Wang J, Ghosh S. Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR<sup>-/-</sup> mice--role of intestinal permeability and macrophage activation. *PLoS One*. 2014;9(9):e108577.
63. Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. *Proc Natl Acad Sci U S A*. 2011;108(16):6615-6620.
64. Tan S, Rupasinghe TW, Tull DL, et al. Degradation of curcuminoids by in vitro pure culture fermentation. *J Agric Food Chem*. 2014;62(45):11005-11015.
65. Tan S, Calani L, Bresciani L, et al. The degradation of curcuminoids in a human faecal fermentation model. *Int J Food Sci Nutr*. 2015;66(7):790-796.
66. Lou Y, Zheng J, Hu H, Lee J, Zeng S. Application of ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry to identify curcumin metabolites produced by human intestinal bacteria. *J Chromatogr B Analyt Technol Biomed Life Sci*. 2015;985:38-47.
67. An C-Y, Sun Z-Z, Shen L, Ji H-F. Biotransformation of food spice curcumin by gut bacterium *Bacillus megaterium* DCMB-002 and its pharmacological implications. *Food & Nutrition Research*. 2017;61(1):1412814.
68. Shen L, Liu L, Ji HF. Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications. *Food Nutr Res*. 2017;61(1):1361780.
69. Burapan S, Kim M, Han J. Curcuminoid Demethylation as an Alternative Metabolism by Human Intestinal Microbiota. *J Agric Food Chem*. 2017;65(16):3305-3310.
70. Yu Y, Wu S, Li J, et al. The effect of curcumin on the brain-gut axis in rat model of irritable bowel syndrome: involvement of 5-HT-dependent signaling. *Metab Brain Dis*. 2015;30(1):47-55.
71. Xu Y, Ku B, Cui L, et al. Curcumin reverses impaired hippocampal neurogenesis and increases serotonin receptor 1A mRNA and brain-derived neurotrophic factor expression in chronically stressed rats. *Brain Res*. 2007;1162:9-18.
72. Funk JL, Oyarzo JN, Frye JB, et al. Turmeric extracts containing curcuminoids prevent experimental rheumatoid arthritis. *J Nat Prod*. 2006;69(3):351-355.
73. Dou Y, Luo J, Wu X, et al. Curcumin attenuates collagen-induced inflammatory response through the "gut-brain axis". *J Neuroinflammation*. 2018;15(1):6.
74. Behal R, Mali AM, Gilda SS, Paradkar AR. Evaluation of local drug-delivery system containing 2% whole turmeric gel used as an adjunct to scaling and root planing in chronic periodontitis: A clinical and microbiological study. *J Indian Soc Periodontol*. 2011;15(1):35-38.
75. Amalraj A, Varma K, Jacob J, et al. A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study. *J Med Food*. 2017;20(10):1022-1030.

76. Kuptniratsaikul V, Thanakhumtorn S, Chinswangwatanakul P, Wattanamongkonsil L, Thamlikitkul V. Efficacy and safety of *Curcuma domestica* extracts in patients with knee osteoarthritis. *J Altern Complement Med*. 2009;15(8):891-897.
77. Khajehdehi P, Zanjanejad B, Aflaki E, et al. Oral supplementation of turmeric decreases proteinuria, hematuria, and systolic blood pressure in patients suffering from relapsing or refractory lupus nephritis: a randomized and placebo-controlled study. *J Ren Nutr*. 2012;22(1):50-57.
78. Ghalaut VS, Sangwan L, Dahiya K, Ghalaut PS, Dhankhar R, Saharan R. Effect of imatinib therapy with and without turmeric powder on nitric oxide levels in chronic myeloid leukemia. *J Oncol Pharm Pract*. 2012;18(2):186-190.
79. Kuttan R, Sudheeran PC, Josph CD. Turmeric and curcumin as topical agents in cancer therapy. *Tumori*. 1987;73(1):29-31.
80. Prucksunand C, Indrasukhsri B, Leethochawalit M, Hungspreugs K. Phase II clinical trial on effect of the long turmeric (*Curcuma longa* Linn) on healing of peptic ulcer. *Southeast Asian J Trop Med Public Health*. 2001;32(1):208-215.
81. Khajehdehi P, Pakfetrat M, Javidnia K, et al. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-beta and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study. *Scand J Urol Nephrol*. 2011;45(5):365-370.
82. Wickenberg J, Ingemansson SL, Hlebowicz J. Effects of *Curcuma longa* (turmeric) on postprandial plasma glucose and insulin in healthy subjects. *Nutr J*. 2010;9:43.
83. Bundy R, Walker AF, Middleton RW, Booth J. Turmeric extract may improve irritable bowel syndrome symptomatology in otherwise healthy adults: a pilot study. *J Altern Complement Med*. 2004;10(6):1015-1018.
84. Shimouchi A, Nose K, Takaoka M, Hayashi H, Kondo T. Effect of dietary turmeric on breath hydrogen. *Dig Dis Sci*. 2009;54(8):1725-1729.
85. Polasa K, Raghuram TC, Krishna TP, Krishnaswamy K. Effect of turmeric on urinary mutagens in smokers. *Mutagenesis*. 1992;7(2):107-109.
86. Hastak K, Lubri N, Jakhi SD, et al. Effect of turmeric oil and turmeric oleoresin on cytogenetic damage in patients suffering from oral submucous fibrosis. *Cancer Lett*. 1997;116(2):265-269.
87. Kim JH, Gupta SC, Park B, Yadav VR, Aggarwal BB. Turmeric (*Curcuma longa*) inhibits inflammatory nuclear factor (NF)-kappaB and NF-kappaB-regulated gene products and induces death receptors leading to suppressed proliferation, induced chemosensitization, and suppressed osteoclastogenesis. *Mol Nutr Food Res*. 2012;56(3):454-465.
88. Lantz RC, Chen GJ, Solyom AM, Jolad SD, Timmermann BN. The effect of turmeric extracts on inflammatory mediator production. *Phytomedicine*. 2005;12(6-7):445-452.
89. Nair A, Amalraj A, Jacob J, Kunnumakkara AB, Gopi S. Non-Curcuminoids from Turmeric and Their Potential in Cancer Therapy and Anticancer Drug Delivery Formulations. *Biomolecules*. 2019;9(1).
90. Srinivas L, Shalini VK, Shylaja M. Turmerin: a water soluble antioxidant peptide from turmeric [*Curcuma longa*]. *Arch Biochem Biophys*. 1992;292(2):617-623.
91. Cohly HH, Taylor A, Angel MF, Salahudeen AK. Effect of turmeric, turmerin and curcumin on H2O2-induced renal epithelial (LLC-PK1) cell injury. *Free Radic Biol Med*. 1998;24(1):49-54.
92. Chethankumar M, Srinivas L. New biological activity against phospholipase A2 by Turmerin, a protein from *Curcuma longa* L. *Biol Chem*. 2008;389(3):299-303.
93. Lekshmi PC, Arimboor R, Raghu KG, Menon AN. Turmerin, the antioxidant protein from turmeric (*Curcuma longa*) exhibits antihyperglycaemic effects. *Nat Prod Res*. 2012;26(17):1654-1658.
94. Sandur SK, Pandey MK, Sung B, et al. Curcumin, demethoxycurcumin, bisdemethoxycurcumin, tetrahydrocurcumin and turmerones differentially regulate anti-inflammatory and anti-proliferative responses through a ROS-independent mechanism. *Carcinogenesis*. 2007;28(8):1765-1773.
95. Murakami A, Furukawa I, Miyamoto S, Tanaka T, Ohigashi H. Curcumin combined with turmerones, essential oil components of turmeric, abolishes inflammation-associated mouse colon carcinogenesis. *Biofactors*. 2013;39(2):221-232.

96. Bagad AS, Joseph JA, Bhaskaran N, Agarwal A. Comparative Evaluation of Anti-Inflammatory Activity of Curcuminoids, Turmerones, and Aqueous Extract of *Curcuma longa*. *Adv Pharmacol Sci*. 2013;2013:805756.
97. Liu J, Zhang Z, Gao J, Xie J, Yang L, Hu S. Downregulation effects of beta-elemene on the levels of plasma endotoxin, serum TNF-alpha, and hepatic CD14 expression in rats with liver fibrosis. *Front Med*. 2011;5(1):101-105.
98. Li G, Xie B, Li X, et al. Down-regulation of survivin and hypoxia-inducible factor-1 alpha by beta-elemene enhances the radiosensitivity of lung adenocarcinoma xenograft. *Cancer Biother Radiopharm*. 2012;27(1):56-64.
99. Sun XY, Zheng YP, Lin DH, Zhang H, Zhao F, Yuan CS. Potential anti-cancer activities of Furanodiene, a Sesquiterpene from *Curcuma wenyujin*. *Am J Chin Med*. 2009;37(3):589-596.
100. Oh OJ, Min HY, Lee SK. Inhibition of inducible prostaglandin E2 production and cyclooxygenase-2 expression by curdione from *Curcuma zedoaria*. *Arch Pharm Res*. 2007;30(10):1236-1239.
101. Hou XL, Hayashi-Nakamura E, Takatani-Nakase T, et al. Curdione Plays an Important Role in the Inhibitory Effect of *Curcuma aromatica* on CYP3A4 in Caco-2 Cells. *Evid Based Complement Alternat Med*. 2011;2011:913898.
102. Xia Q, Wang X, Xu DJ, Chen XH, Chen FH. Inhibition of platelet aggregation by curdione from *Curcuma wenyujin* essential Oil. *Thromb Res*. 2012;130(3):409-414.
103. Sun DI, Nizamutdinova IT, Kim YM, et al. Bisacurone inhibits adhesion of inflammatory monocytes or cancer cells to endothelial cells through down-regulation of VCAM-1 expression. *Int Immunopharmacol*. 2008;8(9):1272-1281.
104. Chakraborty S, Karmenyan A, Tsai JW, Chiou A. Inhibitory effects of curcumin and cyclocurcumin in 1-methyl-4-phenylpyridinium (MPP(+)) induced neurotoxicity in differentiated PC12 cells. *Sci Rep*. 2017;7(1):16977.
105. Fu M, Chen L, Zhang L, Yu X, Yang Q. Cyclocurcumin, a curcumin derivative, exhibits immune-modulating ability and is a potential compound for the treatment of rheumatoid arthritis as predicted by the MM-PBSA method. *Int J Mol Med*. 2017;39(5):1164-1172.
106. Kim K, Kim JJ, Jung Y, et al. Cyclocurcumin, an Antivasoconstrictive Constituent of *Curcuma longa* (Turmeric). *J Nat Prod*. 2017;80(1):196-200.
107. Lai CS, Liao SN, Tsai ML, et al. Calebin-A inhibits adipogenesis and hepatic steatosis in high-fat diet-induced obesity via activation of AMPK signaling. *Mol Nutr Food Res*. 2015;59(10):1883-1895.
108. Tyagi AK, Prasad S, Majeed M, Aggarwal BB. Calebin A, a novel component of turmeric, suppresses NF-kappaB regulated cell survival and inflammatory gene products leading to inhibition of cell growth and chemosensitization. *Phytomedicine*. 2017;34:171-181.
109. Zeng Y, Qiu F, Takahashi K, Liang J, Qu G, Yao X. New sesquiterpenes and calebin derivatives from *Curcuma longa*. *Chem Pharm Bull (Tokyo)*. 2007;55(6):940-943.
110. An JF, Sun Y, Zhang QL, Zhang FL, Zhang JL. The effects of germacrone on lipopolysaccharide-induced acute lung injury in neonatal rats. *Cell Mol Biol (Noisy-le-grand)*. 2014;60(4):8-12.
111. Guo YR, Choung SY. Germacrone Attenuates Hyperlipidemia and Improves Lipid Metabolism in High-Fat Diet-Induced Obese C57BL/6J Mice. *J Med Food*. 2017;20(1):46-55.
112. Srivilai J, Waranuch N, Tangsumranjit A, Khorana N, Ingkaninan K. Germacrone and sesquiterpene-enriched extracts from *Curcuma aeruginosa* Roxb. increase skin penetration of minoxidil, a hair growth promoter. *Drug Deliv Transl Res*. 2018;8(1):140-149.
113. Madhu K, Chanda K, Saji MJ. Safety and efficacy of *Curcuma longa* extract in the treatment of painful knee osteoarthritis: a randomized placebo-controlled trial. *Inflammopharmacology*. 2013;21(2):129-136.